August 2012
-
According to AstraZeneca, the European Commission has approved the Duaklir Genuair aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of the product… Read more . . .
-
According to Sandoz, Ireland and the Czech Republic have approved marketing applications for the AirFluSal Forspiro salmeterol/fluticasone DPI in 50-250 and 50-500 µg dosage forms for the treatment of asthma and/or COPD. The Czech approval… Read more . . .
-
GSK Australia has announced that it plans to invest AUD31 million in blow-fill-seal equipment for the manufacture of Venolin salbutamol nebules at its facility in Boronia, a suburb of Melbourne. The company cited increasing demand… Read more . . .
-
CDMO Catalent has announced its acquisition of particle size reduction specialist Micron Technologies, which offers micronization, milling, and particle characterization services for pharmaceutical products, including inhalation powders. Catalent notes that it offers development through to… Read more . . .
-
US-based AirWare Labs says that it has filed patent applications for an intranasal drug delivery system that will include “AirWare Labs’ patent-pending disposable sealed cartridge and patent-pending nasal insert system with insufflation plugins, both of… Read more . . .
-
The US Patent and Trademark Office (USPTO) has awarded US Patent No 8,883,728, “Intranasal administration of active agents to the central nervous system,” to Aegis Therapeutics, the company said. The patent covers, “Pharmaceutical compositions and… Read more . . .
-
The Bill and Melinda Gates Foundation has awarded a $2.5 million grant to researchers at Liverpool School of Tropical Medicine (LSTM) for a study to determine the effects of nasal spray flu vaccine on pneumococcal… Read more . . .
-
According to Avanir Pharmaceuticals,the FDA has issued a Discipline Review letter in response to the company’s NDA for AVP-825 intranasal dry powder sumatriptan requesting that the company “optimize the product-user interface” and conduct additional human… Read more . . .
-
The Australian Research Council has awarded a $521,800 grant to Daniela Traini and Paul Young of the Woolcock Institute’s RespiTech group and Patrick Spicer of the University of New South Wales for development of inhalable… Read more . . .
-
As AstraZeneca completes the acquisition of Almirall’s respiratory drug franchise, which was first announced in July 2014, Almirall says that 719 employees will transfer to AstraZeneca. The deal includes the inhalation R&D company Almirall Sofotec… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland